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The  purpose  of  this  investigation  was  to  evaluate  the  budget  impact  and
cost-effectiveness  of  direct-acting  antivirals  (DAAs)  for  the  treatment  of
hepatitis C virus (HCV) infection in Hong Kong. A decision analytic model
was developed to compare short-term costs  and health  outcomes of  patients
with chronic HCV genotype 1 infection in Hong Kong who were treated with
an interferon (INF)-based treatment (dual therapy of pegylated interferon and
ribavirin)  or  DAA-based  treatments  (sofosbuvir  or  ledipasvir/sofosbuvir  or
ombitasvir/paritaprevir/ritonavir and plus dasabuvir). Compared to INF-based
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treatment,  DAA-based  treatments  yielded  an  incremental  cost  of
$24,677–$31,171 per  course while improving the rate of  sustained virologic
response (SVR) from 59–66% to 82.3–99.8%. The incremental cost-effective
ratios of DAA-based treatments ranged from $9724 to $29,189 per treatment
success, which were all  below the cost-effectiveness threshold of local GDP
per capita ($42,423 in 2015). Introducing DAAs resulted in a 126.1% ($383.7
million) budget increase on HCV infection management over 5 years. A 50%
change in DAA medication costs reflected a change in the incremental budget
from  $55.2  to  $712.3  million.  DAA-based  treatments  are  cost-effective
alternatives to INF-based treatment in Hong Kong. Introducing DAAs to the
public  hospital  formulary  yields  a  considerable  budget  increase  but  is  still
economically favorable to the local government.
Electronic supplementary material
The online version of this article (doi: 10.1007/s10096-017-2995-7 ) contains
supplementary material, which is available to authorized users.
Globally, 2–3% of the population is infected with hepatitis C virus (HCV) and
55–85% become chronic infections with increased morbidity and mortality [1].
Approximately 700,000 deaths were attributed to chronic HCV infection each
year in 1990–2010 [2], most of which were caused by persistent HCV infection
resulting in liver cirrhosis and hepatocellular carcinoma [3, 4]. Chronic HCV
infection-related economic burden is also considerable. In the USA, the average
lifetime cost of an individual with chronic HCV infection was estimated at
$64,490 in 2011, which was 130% of the GDP per capita; the associated total
healthcare costs were estimated to be $6.5 billion during the same year and
expected to peak at $9.1 billion in 2024 [5].
As no vaccine is currently available for HCV infection, the infection control is
largely dependent on antiviral medications. The standard treatment for HCV
infection has undergone a remarkable transformation in recent years from
parenteral indirect-acting therapy with ∼50% treatment success along with
frequent adverse events to oral direct-acting antivirals (DAAs) with greatly
improved efficacy, safety, and tolerability profiles and shortened treatment
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durations [6, 7, 8].
In Hong Kong, several DAAs have been approved by the Drug Office as
alternatives to interferon (INF)-based treatment, but only a few DAAs were
listed in the public hospital formulary. In addition to safety and efficacy,
pharmacoeconomic evaluations including cost-effectiveness and budget impact
are among the three principle considerations for drug listing and subsidization by
the government [9, 10]. Despite the cost-effectiveness of DAAs having been well
established in overseas studies [11, 12, 13, 14, 15, 16, 17, 18], the conclusions
were largely subject to patient profiles and local economic factors. The
demonstration of their potential cost and health benefits to the local Hong Kong
population remains limited. The primary objective of this study is to evaluate the
5-year budget impact of introducing DAAs for HCV treatments to the public
hospital formulary to assess the government affordability. A short-term
cost-effectiveness evaluation of DAA-based treatments compared to INF-based
treatment was also conducted to assist shared decision-making from
pervasivekey stakeholders.
A decision analytic model was developed using Microsoft Excel (2010) with the
model framework recommended by the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR) guideline for
cost-effectiveness and budget impact analyses (Fig. 1) [19]. The model was
applied to simulate short-term health outcomes of chronic HCV infection during
the treatment period and estimate the cost incurred from medication, clinical
management, and adverse drug reactions (ADRs). Target patients were assigned
to receive INF- or DAA-based treatments according to the market share of each
treatment option. The total cost per treatment success and government healthcare
expenditure over 5 years were estimated to assess the cost-effectiveness of
DAA-based treatments and the budget impact of introducing DAAs to the
formulary. Key elements and assumptions of the model are detailed in
Supplemental Table 1.
Fig. 1
Decision  analytical  model  structure.  ADR  Adverse  drug  reaction;  DAAs  direct-
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acting  antivirals;  INF  interferon;  LED/SOF  ledipasvir/sofosbuvir;  pegINF
pegylated  interferon;  SOF  sofosbuvir;  SVR  sustained  virologic  response;  RBV
ribavirin; VP ombitasvir/paritaprevir/ritonavir andplus dasabuvir
Competing alternatives were INF-based treatment versus available DAA-based
treatments in Hong Kong for patients with HCV genotype 1 (including genotypes
1a and 1b) infection (Table 1). The INF-based treatment was dual therapy of
pegylated interferon (pegIFN, PEGasys®) and ribavirin (RBV, Copegus®).
DAA-based treatments included three options from the second-generation DAAs:
sofosbuvir (SOF, Sovaldi®), ledipasvir/sofosbuvir (LED/SOF, Harvoni®), and
ombitasvir/paritaprevir/ritonavir andplus dasabuvir (VP, Viekira Pak®). All
DAAs may be prescribed as a single drug or in combination with pegIFN and
RBV, depending on the patient treatment history and cirrhotic conditions.
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Treatment regimens settings in the model (Supplemental Table 2) were based on
the recommendations for testing, managing, and treating hepatitis C from the
American Association for the Study of Liver Diseases (AASLD)/Infectious
Diseases Society of America (IDSA) [20].
Table 1
Treatments for hepatitis C virus (HCV) infection (genotypes 1a and 1b)
Dosage Route Dosageregimen
Treatment
duration
INF-based treatment
 Pegylated interferon
(pegIFN) 180 μg
Subcutaneous
injection
Once a
week 48
+ Ribavirin (RBV) 800–1200 mg Oral Twicedaily
DAA-based treatments
 Sofosbuvir (SOF) 400 mg Oral Oncedaily 12
 Ledipasvir/sofosbuvir
(LED/SOF) 90/400 mg Oral
Once
daily 12
 Ombitasvir/paritaprevir
/ritonavir and plus
dasabuvir (VP, Viekira
Pak®)
25/150/100 mg
250 mg
Oral
Oral
Once
daily
Twice
daily
12–24
DAA Direct-acting antivirals; INF interferon
The analysis was conducted from a public institutional perspective of Hong
Kong with relevant direct medical costs considered. The analytical time horizon
was 5 years and all costs were discounted at 4% per year given the typical range
of 3–5% in the health economic literature [21]. Costs are presented as the value
in US dollars in 2015 (1 US dollar to 7.76 HK dollars).
This study focused on patients with chronic HCV genotype 1 infection, which
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accounted for approximately 70% of the overall HCV chronic infections in Hong
Kong [22]. It was assumed all HCV-positive individuals were treated and that
treatment was only required once. Therefore, all prevalent cases in year one of
the study were treated and then all incident cases were treated in each subsequent
year for the remainder of the study period. Target population identification is
illustrated in Fig. 2. Treatment regimens depended on HCV genotype (1a or 1b),
cirrhosis condition (with or without cirrhosis), and treatment history
(treatment-naïve or treatment-experienced), resulting in patients being
categorized into eight groups and analyzed separately.
Fig. 2
Flow and sources for target population identification
Epidemiological and clinical inputs of the decision analytical model are
summarized in Supplemental Table 3. Approximately 0.3% (n = 21,869) of the
population in Hong Kong was HCV-positive, with an average of 563 new cases
diagnosed annually from 2004 to 2014 [23].Correspondingly, the number of
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patients treated in year 1 and the subsequent 4 years were set to be 12,675 and
330 in the model according to the proportion of chronic genotype 1 infections in
Hong Kong [22]. Treatment-naïve (TN) was defined as patients who had never
received any treatment for HCV infection. Treatment-experienced (TE) was
defined as patients who had received IFN-based therapy but failed to achieve
sustained virologic response (SVR) after completion of the treatment [24]. The
proportion of TE patients was adopted from two local hospital-based longitudinal
studies, while the rates of SVR and incidences of ADR for each treatment were
based on relevant international landmark trials (data sources detailed in
Supplemental Table 3 and Supplemental References).
Key economic inputs of the model are summarized in Supplemental Table 4.
Medication cost was calculated by multiplying the wholesale acquisition cost of
drugs by the corresponding treatment duration. In the absence of local drug price
information, wholesale acquisition costs were estimated by multiplying HCV
drug prices in the UK with the drug price ratio between HK and the UK. It was
estimated that the UK:HK price ratio of oral anticoagulants was 0.89 in the
previous study of our research group (data not published), which was used for
the estimation of HCV treatment costs in this study.
Clinical management cost was calculated by multiplying outpatient charges for
specialist clinic (SOPC) attendance by the clinical visit frequency for treatment
and the control of ADRs. Only common ADRs managed in the SOPC were
considered. Serious ADRs that needed inpatient treatment were not included
given the rare incidence observed in clinical trials. Under the public healthcare
system of Hong Kong, the charge for medical attendance in the SOPC covers the
costs of prescriptions, pathology investigations, radiology, and other
examinations; therefore, it was considered as the overall estimation of clinical
management cost [25]. The frequency of clinical visits required for receiving the
treatment and managing the ADRs was based on the AASLD/IDSA guideline and
a previous budget impact study, respectively [20, 26].
Before the introduction of DAAs, INF-based treatment accounted for 100% of
the market share. After the introduction, the market shares for each DAA in years
1 and 2 of the study were referenced from US prescription volume data,
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considering similar timing and drug approval policy as that in Hong Kong.
However, the market shares in the 3  to 5  years were assumed in this study, as
market data were not available at the time of the study.
In the cost-effectiveness analysis (CEA), outcomes included total treatment
costs, incremental rate of SVR, and incremental cost-effectiveness ratio (ICER),
defined as the incremental cost per treatment success for each individual.
Treatment with ICER less than one local GDP per capita ($42,423 in 2015) was
considered cost-effective. In the budget impact analysis (BIA), changes of
government healthcare expenditure on HCV infection management before and
after the introduction of DAAs were assessed.
The analyses were performed under the best scenario assuming that all target
patients received one of the treatments and no occurrence of premature treatment
discontinuation or switch. The effect of uncertainties on the base-case results was
evaluated by one-way sensitivity analysis (SA). The clinical parameter
[proportion of TE patients (20–60%)] and economic parameters [medication cost
of DAAs (±50%) and market share of all treatments (±5%)] were tested under the
predefined ranges to evaluate the robustness of results. All tested parameters
were ranked according to the descending order of variation in base-case results
and presented in tornado diagrams. Model inputs were entered, cross-checked,
and analyzed independently by two authors (XL and NSC).
The cost-effectiveness of DAA-based treatments against INF-based treatment is
shown in Table 2. As the major cost component, medication costs accounted for
over 60% and 95% of the total treatment costs for INF and DAA-based
treatments, respectively. In general. , DAA-based treatments cost 2.1–2.4 times
as much as INF-based treatment, regardless of patient cirrhosis condition or
treatment history. Among the three DAA-based treatments, the incremental cost
by descending order was LED/SOF ($29,734–$31,171), SOF ($29,380), and VP
($24,677–$27,794).
rd th
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Table 2
Cost-effectiveness analysis (CEA) of INF-based versus DAA-based treatments by treatment e
Patient type Treatments Medicationcost ($)
Management
cost ($)
Total
cost
($)
Incremental
cost ($)
S
Treatment-naïve
without
cirrhosis
pegIFN and
RBV 13,477 8215 21,692 Reference 6
SOF 48,656 2416 51,072 29,380 8
LED/SOF 50,460 966 51,426 29,734 9
VP 45,403 966 46,369 24,677 9
Treatment-naïve
with cirrhosis
pegIFN and
RBV 13,477 8215 21,692 Reference 6
SOF 48,656 2416 51,072 29,380 8
LED/SOF 50,460 966 51,426 29,734 9
VP 48,488 998 49,486 27,794 9
Treatment-
experienced
without
cirrhosis
pegIFN and
RBV 13,477 8215 21,692 Reference 5
SOF 48,656 2416 51,072 29,380 8
LED/SOF 50,460 966 51,426 29,734 8
VP 45,403 966 46,369 24,677 9
Treatment-
experienced
with cirrhosis
pegIFN and
RBV 13,477 8215 21,692 Reference 6
SOF 48,656 2416 51,072 29,380 8
LED/SOF 51,897 966 52,863 31,171 9
VP 48,488 998 49,486 27,794 9
ICER Incremental cost-effectiveness ratio, defined as incremental cost per treatment succ
Cost per treatment success = total treatment cost/SVR
Compared to INF-based treatment, all DAA-based treatments yielded improved
treatment success with an incremental rate of SVR between 16.3 and 40.7%. The
cost per treatment success for INF-based treatment ranged from $32,867 to
a
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$36,767, with corresponding costs for DAA-based treatments increasing by
1.5–1.9-fold. Using INF-based treatment as the reference group, the ICERs of
DAA-based treatments ranged from $9742 to $29,189 per treatment success,
which were all below the predefined cost-effectiveness threshold.
Government healthcare expenditure on HCV infection management was
estimated to increase steadily from $280.0 to $304.4 million in 5 years if
INF-based treatment was the only option. Introducing DAAs to the formulary
was associated with a 126.1% ($383.7 million) increase in budget, with a
maximum healthcare expenditure of $688.1 million at year 5 (Fig. 3).
Fig. 3
Healthcare expenditure before and after the introduction of DAAs
Breakdowns of the total healthcare expenditure before and after the introduction
of DAAs are illustrated in Fig. 4. Upon the introduction of DAAs, the share of
medication cost increased from 61.5% to 96.7%, with a simultaneously decreased
share of treatment management cost from 36.7% to 3.1%. The clinical
management cost for ADRs decreased 4.2-fold after the introduction of DAAs,
although it consistently accounted for less than 2% of the total healthcare
expenditure before (1.8%) and after (0.2%) the introduction.
Fig. 4
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Breakdown of 5-year healthcare expenditure before and after the introduction of
DAAs
Variations of incremental healthcare expenditure caused by parameter
uncertainties are illustrated in Fig. 5. Fifty percent of the fluctuation in the
medication costs of DAAs caused the greatest variation of the increased budget.
When all DAAs were introduced with halved drug acquisition costs, the
incremental healthcare expenditure was estimated to be reduced from $383.7
million at base case to $55.2 million. In the meanwhile, if the medication costs
increased to 150% of our base-case estimation, the budget is expected to increase
by $712.3 million. Among all the uncertainties in market shares, a 5% fluctuation
in the market share of INF-based treatment had the greatest impact on
expenditure ($365.3 to $402.2 million). The market share of DAAs had limited
impact on the base-case analysis, as there were only marginal changes in
incremental healthcare. The incremental healthcare expenditure ($383.2 to 384.3
million) was positively associated with the proportion of TE patients; however,
the impact was minimal among all tested parameters.
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Fig. 5
Tornado diagram for  one-way sensitivity  analysis.  DAA  Direct-acting antivirals;
INF  interferon;  LED/SOF  ledipasvir/sofosbuvir;  SOF  sofosbuvir;  TE  treatment-
experienced; VP ombitasvir/paritaprevir/ritonavir andplus dasabuvir
Despite the relatively low prevalence of HCV infection in the general population
of Hong Kong (0.3% in 2001), the infection was commonly found in injecting
drug users (66.8%), patients with hemophilia (56%), and hemodialysis (4.6%)
and other patients requiring frequent blood/blood product transfusions [23]. The
control of HCV infection remains an important public health issue. The
landscape of HCV treatment is undergoing a revolutionary change from
parenteral IFN-based to all-oral DAA-based treatment regimens in recent years.
Second-generation DAAs not only provide IFN-free treatments with > 95% SVR
and lower incidence of ADRs, but also decrease treatment duration by 50% to
12–24 weeks [27, 28]. These new treatments are rapidly growing in the market
but are costly for patients [29]. Hence, drug listing and subsidization are
important factors impacting potential accessibility and uptake. Cost-effectiveness
studies of DAA-based treatments have been conducted broadly in Europe, USA,
Australia, and Asian countries, with the majority estimating the ICERs of new
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treatments to be within the accepted range of medical practices and willingness-
to-pay [5, 11, 12, 13, 14, 15, 16, 17, 18, 30, 31, 32]. However, there are derived
assumptions on population profile, disease progression, and economic factors
across various models, which limited their generalizability. It is also well
recognized that each healthcare jurisdiction has its own unique system and no
international studies and recommendations are fully applicable to local drug
policies [10]. To the best of our knowledge, this is the first population-based
health economic evaluation of DAA-based treatments in Hong Kong to explore
their potential to be listed in the public hospital formulary.
Unlike traditional CEA studies using quality-adjusted life years as the long-term
measurement of health outcomes [11, 12, 18, 30, 31, 32], a simplified decision
analytic model was used to assess the cost-effectiveness of different treatments
during the treatment course (12–48 weeks) to provide timely costs data relevant
to stakeholders, including clinicians, patients, and policymakers. This study
indicated that the medication cost of DAA-based treatments was more than twice
that of the INF-based treatment; however, the total cost per treatment success
was partially paid off by the greatly shortened treatment duration and improved
rate of SVR. Consistent with the current literature, it was not surprising to find
that the three DAA-based treatments were cost-effective in all of the scenarios,
regardless of patient treatment history or cirrhosis condition, given that the
ICERs were all less than the GDP per capita, which is - the commonly accepted
willingness-to-pay threshold for cost-effectiveness evaluations [33]. In addition,
although this study was not designed to compare the three options within the
DAA-based treatment group, it is interesting to find that VP is the most
cost-effective DAA-based treatment, with lowest ICER for all groups of patients.
Financing the overall healthcare costs for all patients with HCV infection
remains a global challenge given the excluded cases that were undiagnosed,
untreated, discontinued treatment, or failed to respond to treatments [34, 35, 36,
37]. The present BIA was intended to maximize the required healthcare
expenditure by setting all of the target patients treated and assuming no
discontinuation occurred over the analytical time horizon. From this perspective,
introducing DAAs to the formulary was estimated to increase the government
budget of HCV management by 126.1% ($383.7million) over 5 years.
Apparently, the introduction required considerable investment from end-payers
in the short term. However, with the greatly improved rate of SVR of up to 99%,
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DAA-based treatments are offering promising cure therapies for HCV infection.
More importantly, patients with chronic HCV infection are at risk for progressive
liver fibrosis, cirrhosis, portal hypertension, hepatocellular carcinoma, and
decompensated liver disease [38, 39, 40]. Since more patients are expected to be
successfully treated by DAA-based treatments, the introduction of DAAs has
greater potential for saving healthcare resources and expenditures for the
management of hepatitis C-related comorbidities in the long term.
The average total healthcare expenditure as a percentage of GDP was
approximately 5% in Hong Kong in the past 10 years [41], which is equivalent to
$15.50 billion in 2015 [42]. Based on these estimates, the increased budget on
HCV infection management accounted for 2.5% of the overall healthcare
expenditure in 2015. It might indicate that introducing DAA-based treatments to
the formulary is affordable to the government. It is noted that clinical
management costs for receiving the treatment and managing ADRs were largely
decreased after introducing DAAs. It is meaningful for saving clinical healthcare
resources in public hospitals, which is known to be always demanding and
insufficient. Last but not least, despite the foreseeable health and economic
benefits of DAA-based treatments, medication costs were found to be the major
economic burden at both the individual and population levels. Strategically
reducing medication costs will be the key determinant to further lowering the
healthcare cost for individuals and society as a whole.
Several limitations were acknowledged in this study. Firstly, in line with the
majority of landmark trials for DAA-based treatments [43, 44, 45, 46, 47, 48],
we restricted the regiments to genotype 1 infection only. Although it is the most
common genotype of HCV in Hong Kong, the real healthcare expenditure on
HCV management is expected to be greater than our estimation. Secondly, key
clinical parameters including SVR and incidences of ADRs were extracted from
phase III clinical trials of predominately Caucasian patients. It may not
completely reflect the real treatment efficacy and safety in Asian patients. Local
epidemiological and clinical studies are required to provide data inputs for more
realistic estimation in Hong Kong Chinese patients. Thirdly, this study was
restricted to providing short-term health economic insights on DAA-based
treatments in Hong Kong. Long-term health outcomes of hepatitis C-related
morbiditiessequelae such as cirrhosis, hepatocellular carcinoma and liver failure,
and mortality and the relevant costs were not measured. The important impact of
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preventingon of further transmission of HCV infection upon successful
eradication by DAAs was also not assessed.
In conclusion, DAA-based treatments are cost-effective alternatives to INF-based
treatment for patients with chronic genotype 1 HCV infection in Hong Kong.
Introducing DAAs to the public hospital formulary yields a considerable budget
increase but is still economically favorable to the local government.
Comprehensive analysis considering other HCV genotypes, long-term health and
economic outcomes, and advanced sensitivity analyses are warranted for future
studies.
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